Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
The ASCO Conference
Every year, Gustave Roussy participates in the American Society of Clinical Oncology (ASCO) conference, a major event in cancer research held in Chicago, United States.
A conference dedicated to the clinical development of the latest advances in oncology
Focused on advancing clinical research in oncology, the ASCO Annual Meeting brings together thousands of cancer specialists from around the world each year to discuss the latest advances in the treatment of cancer patients.
Each year, physician-researchers from Gustave Roussy present their studies, thereby highlighting the Institute’s expertise.
-
50,000
members*
-
150
From more than 150 countries*
Gustave Roussy at the ASCO Annual Meeting: A Look Back at Past Editions
Experts from Gustave Roussy participated in 107 presentations, showcasing studies that demonstrated the Institute’s expertise in antibody-drug conjugates and new therapeutic approaches.
Physicians and researchers at Gustave Roussy participated in 109 presentations. They presented several studies highlighting the benefits of immunotherapy, the development of targeted therapies, and new treatment combinations.
Experts from Gustave Roussy gave 135 presentations. In particular, they presented studies highlighting antibody-drug conjugates, screening, the development of new therapeutic strategies (immunotherapy, targeted therapies, nuclear medicine), as well as innovative approaches to personalized treatment and patient follow-up.
- Promising Results for an Antibody Conjugate in Lung Cancer, by Prof. David Planchard
- Early detection of depressive symptoms in breast cancer, by Dr. Antonio Di Meglio
- Virtual biopsy: AI enables mapping of the immune response in tumor lesions, by Dr. Roger Sun
- Certain socioeconomic factors influence adherence to a telemonitoring system, by Dr. Maria Alice Franzoi
At the 2023 ASCO meeting, physician-researchers from Gustave Roussy delivered approximately 50 presentations highlighting new therapeutic strategies to benefit patients.
- Predictive Biomarkers for the Efficacy of Targeted Dual Therapy in Metastatic Lung Cancer with EGFR Mutations, by Prof. Benjamin Besse
- The BIOMEDE study systematizes molecular profiling to guide diagnosis and management of infiltrating brainstem glioma, by Dr. Jacques Grill
- Metastatic prostate cancer with DNA repair gene mutations: a highly promising combination of hormone therapy and a PARP inhibitor, by Prof. Karim Fizazi
- Benefits of radiation therapy combined with abiraterone and standard treatment in minimally metastatic prostate cancer, by Dr. Alberto Bossi
- Urinary Tract Cancers – Evidence of the Superiority of Targeted Therapy Over Standard Treatment, by Dr. Yohann Loriot
Experts at Gustave Roussy were among the first and most recent authors of landmark clinical trials. Forty-eight of their studies were selected for presentation at ASCO. These studies demonstrated advances in targeted therapies and immunotherapy, as well as innovative strategies to improve access to treatments and the management of complex cancers.
- Promising Targeted Therapy for IDH2-Mutated Acute Myeloid Leukemias, by Dr. Stéphane de Botton
- RAGNAR Study: The Benefits of Targeted Therapy Beyond Bladder Cancer, by Dr. Yohann Loriot
- The SACHA Study Ensures the Safe Use of Innovative Anticancer Drugs in Children Outside of Clinical Trials, by Prof. Gilles Vassal
- “2-in-1” Immunotherapy for Advanced Kidney Cancer, by Prof. Laurence Albiges
Physicians and researchers at Gustave Roussy participated in more than 100 presentations, which focused in particular on new generations of immunotherapy and innovative treatment combinations for cancers such as cervical cancer, acute leukemias, and metastatic prostate cancer.
Experts from Gustave Roussy participated in 80 presentations. These studies highlighted, in particular, remote monitoring, antibody-drug conjugates, and innovative treatment combinations, as well as the identification of predictive biomarkers in several types of cancer.
- The CAPRI system demonstrates its clinical efficacy for personalized remote monitoring of patients treated with oral anticancer drugs, by Dr. Olivier Mir
- Lung Cancers: Hope from Antibody Conjugates, by Dr. Anas Gazzah
- Pediatric Cancers: Encouraging Initial Results from a Dual-Therapy Approach in the Treatment of Certain Low-Grade Gliomas, by Dr. Birgit Geoerger
- Soft Tissue Sarcomas: The Doxorubicin-Trabectedin Combination Confirms Its Value as a First-Line Treatment for Leiomyosarcomas, by Dr. Patricia Pautier
- Breast Cancers: Certain Genetic Alterations May Predict the Efficacy of Ribociclib, by Prof. Fabrice André
Physicians and researchers at Gustave Roussy participated in 80 presentations selected by ASCO. These studies focused in particular on immunotherapy and targeted therapies, quality-of-life issues, and the role of new technologies in patient care.
At the 2018 ASCO conference, teams from Gustave Roussy presented 70 papers. The studies presented confirmed the Institute’s role in innovative therapeutic strategies, particularly in immunotherapy and molecular medicine, through early-phase trials and research conducted across a wide range of diseases.
Experts from Gustave Roussy participated in 59 presentations, which highlighted the Institute’s advances in immunotherapy, targeted therapies based on molecular medicine, and the development of new diagnostic and prognostic tools to personalize patient care.
For this edition, experts from Gustave Roussy participated in 75 presentations. These studies highlighted the Institute’s advances in three major areas: immunotherapy, precision medicine through targeted therapies, and the optimization of chemotherapy, with several clinical trials led by Gustave Roussy.
At the 2015 ASCO meeting, physician-researchers from Gustave Roussy participated in 56 presentations. These presentations highlighted the Institute’s advances in immunotherapy, targeted therapies, and early-phase clinical trials, with research conducted in particular in adult and pediatric oncology, as well as in several types of cancer.